Skip to main content
. Author manuscript; available in PMC: 2015 May 13.
Published in final edited form as: Vaccine. 2013 Jul 16;32(23):2756–2762. doi: 10.1016/j.vaccine.2013.07.010

Figure 2. Immunogenicity of gB vaccines.

Figure 2

Guinea pigs were immunized with three doses of either gB/FA, gB/AS02V or gB/AS01B at monthly intervals. Geometric mean (GM) (A) anti-gB antibody titers (GMTs), (B) avidity indices and (C) GPCMV neutralizing titers in the immunogenicity cohort of Study 1. Immunogenicity was measured in samples taken at (A–C) 28 days post 1st immunization (28dPI); (A–C) 28 days post 2nd immunization (28dPII); and (A and B) 30 days post 3rd immunization (30dPIII). Error bars describe 95% confidence intervals (95% CIs). GPCMV-specific antibody GMTs were (11–75-fold) higher in each vaccine group after Doses 2 and 3 compared with after Dose 1, but were not significantly different between the three vaccine groups after Dose 3. GMTs were significantly different following Dose 3 than when compared with those following Dose 2 for each group.